Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress -Additional Data, Including Late-Breaking Results from Phase 2 Trial of ALXN1007 in Patients with GI-GVHD, Also to be Presented- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present late-breaking data from a Phase 1/2 dose-escalating study of ALXN1210, the Company’s highly innovative longer-acting C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH). In another late-breaking poster, researchers will present additional results from a Phase 2 trial evaluating ALXN1007 in patients with acute graft-versus-host disease involving the lower...
↧